SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be a valuable route for drug discovery for these diseases. However, care needs to be taken in selection of both the actual drug target and the chemical matter that is developed. In this article, potential criteria to aid target selection are described. Then the physiochemical properties of typical oral drugs are discussed and compared to those of known anti-parasitics
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be...
SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The fe...
This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The fe...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub-Saharan Africa, is usually f...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be...
SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can be...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The fe...
This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The fe...
The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected ...
While treatment options for human African trypanosomiasis (HAT) have improved significantly, there i...
Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub-Saharan Africa, is usually f...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause subst...